-+ 0.00%
-+ 0.00%
-+ 0.00%

BeOne Medicines Partners With CLL Society To Expand Support For Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Resources

Benzinga·11/17/2026 11:07:05
Listen to the news

Through this new three-year Visionary Partnership, BeOne is expanding its support for CLL Society to $3 million, advancing several initiatives that reflect the organization’s evolving approach to supporting the CLL/SLL community — expanding education, digital resources, and engagement programs designed to help patients, care partners, and healthcare providers navigate an increasingly complex treatment landscape, including:

Expanding biomarker testing education through Test Before Treat, an ongoing campaign designed to help healthcare providers, patients, and care partners understand why biomarker testing is an important step before treatment begins and how a patient’s mutation status can help inform more personalized treatment decisions.
Advancing access to trusted digital resources, including AI-enabled search and personalization designed to help patients and care partners more easily find the independent, physician-curated resources most relevant to them, including information on CLL/SLL and evolving treatment options, through a next-generation platform designed to become a trusted destination for CLL/SLL information and resources.
Supporting additional education and community engagement efforts, including expert interviews, webinars, and other programs designed to help people affected by CLL/SLL stay informed and supported.